Phase II trial of piperazinedione in the treatment of advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group Study. 1986

J T Thigpen, and J A Blessing, and H D Homesley, and W Petty

Twenty-three patients with advanced or recurrent endometrial carcinoma no longer amenable to control with surgery and/or radiotherapy were entered into study. Twenty-two actually received therapy with piperazinedione at a dose of 9 mg/m2 intravenously every 3 weeks. One partial responder was observed. Adverse effects were primarily manifested as myelosuppression, and were significant but tolerable. Due to the low order of activity observed, this drug is not recommended for further study in the treatment of endometrial carcinoma.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014594 Uterine Neoplasms Tumors or cancer of the UTERUS. Cancer of Uterus,Uterine Cancer,Cancer of the Uterus,Neoplasms, Uterine,Neoplasms, Uterus,Uterus Cancer,Uterus Neoplasms,Cancer, Uterine,Cancer, Uterus,Cancers, Uterine,Cancers, Uterus,Neoplasm, Uterine,Neoplasm, Uterus,Uterine Cancers,Uterine Neoplasm,Uterus Cancers,Uterus Neoplasm

Related Publications

J T Thigpen, and J A Blessing, and H D Homesley, and W Petty
February 1993, American journal of clinical oncology,
J T Thigpen, and J A Blessing, and H D Homesley, and W Petty
August 2000, Gynecologic oncology,
J T Thigpen, and J A Blessing, and H D Homesley, and W Petty
August 1982, Cancer treatment reports,
J T Thigpen, and J A Blessing, and H D Homesley, and W Petty
June 2003, Gynecologic oncology,
J T Thigpen, and J A Blessing, and H D Homesley, and W Petty
December 2002, Gynecologic oncology,
J T Thigpen, and J A Blessing, and H D Homesley, and W Petty
January 2010, Gynecologic oncology,
J T Thigpen, and J A Blessing, and H D Homesley, and W Petty
January 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J T Thigpen, and J A Blessing, and H D Homesley, and W Petty
February 1990, American journal of clinical oncology,
J T Thigpen, and J A Blessing, and H D Homesley, and W Petty
February 2002, Gynecologic oncology,
J T Thigpen, and J A Blessing, and H D Homesley, and W Petty
June 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!